Novavax’s COVID-19 Shot Finally Authorized In US, But Could Miss Out Again On Bivalent Booster

Still Hoping To Hit $4bn Revenues Despite Slow Start

 
• By Andrew McConaghie
  
Novavax flag
Novavax will not catch up with Pfizer or Moderna, but the vaccine's EUA is nevertheless an inflection point for the company. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

More from Scrip